Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical,
and molecular characteristics from non–small-cell lung cancer. SCLC has high metastatic …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) accounts for 13–15% of all new lung cancer cases in the US.
The tumor has a tendency to disseminate early resulting in 80–85% of patients being …

Background Small cell lung cancer (SCLC) is a lethal disease for which there have been
only small advances in diagnosis and treatment in the past decade. Our goal was to revise …

Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …

Small cell lung cancer (SCLC) is an aggressive malignancy with a distinct natural history
and dismal prognosis. Given its predisposition for early dissemination, patients are …

Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …

Purpose This guideline is for the management of patients with small cell lung cancer (SCLC)
and is based on currently available information. As part of the guideline, an evidence-based …

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer. Although SCLC is
characterised by rapid responses to chemotherapy (ChT) and sensitivity to radiotherapy …

Abstract Treatment of small cell lung cancer (SCLC) remains a significant challenge for the
oncologists. Attempts to improve the results of first-line treatment have all failed so far and no …